Adderall Shortage Persists as Opioid Settlement Triggers Pharmacy Constraints
December 15, 2022The months-long Adderall shortage persists nationwide and is now compounded by new restrictions on pharmacists related to the opioid crisis.
As part of a recent $21 billion settlement, three U.S. pharmaceutical wholesalers accused of contributing to the opioid epidemic agreed to increased monitoring of pharmacy orders thought to be suspicious.
A consequence of this, according to Reuters, has been that pharmacists across the country are being prevented from filling prescriptions for both stimulants, like Adderall, and sedatives, like Xanax, for the same patient.While Xanax and Adderall are not opioids, their high risk for abuse and addiction causes them to be categorized as Schedule II controlled substances, regulated by the government.
Read more on additudemag.com
